Amyloid Solution is developing disease-modifying treatments targeting the underlying pathology of Alzheimer's disease across various stages. Their approach focuses on addressing the complex neurodegenerative processes to improve patient outcomes and slow disease progression.
Funding
$65.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's disease lacks effective treatments that address the underlying pathology and slow disease progression across various stages. Current therapies primarily manage symptoms without modifying the course of the complex neurodegenerative processes involved.
Solution
Amyloid Solution is developing disease-modifying treatments designed to target the root causes of Alzheimer's disease. Their approach aims to provide a comprehensive solution by addressing the diverse pathological alterations present in patients at different stages of the disease. The company's science focuses on developing innovative therapies to overcome the limitations of existing treatments and improve patient outcomes.
Target Audience
The primary target audience includes patients diagnosed with Alzheimer's disease at various stages, as well as healthcare providers and researchers focused on neurodegenerative diseases.
Features
- Development of disease-modifying treatments for Alzheimer's disease.
- Targeting the underlying pathology of Alzheimer's across various stages.
- Focus on addressing complex neurodegenerative processes.
- Innovative therapies designed to improve patient outcomes.